GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 20 Oct, 19:21 UTC

The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular genetic signature. It’s a label expansion for Jemperli, which was initially approved as a treatment for endometrial cancer The post GSK Immunotherapy Gets Accelerated FDA…

science

Sources

• T2GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal CancerFierce Biotech / Fierce Healthcare / MedCity / GEN20 Oct, 19:21